Search Results

K-ASSAY® CRP (Ver.2) is intended to be used for the quantitative determination of C-reactive protein (CRP) in human serum and plasma (potassium-EDTA or lithium-heparin) by immunoturbidimetric assay. Measurement of CRP aids in the detection and evaluation of infection, tissue injury, inflammatory disorders and associated diseases. FOR IN VITRO DIAGNOSTIC USE.

The K-ASSAY® CRP (Ver.2) assay quantifies C-reactive protein based on immunoturbidimetric assay. The reagent uses latex combined with goat polyclonal antibody specific to human CRP. By adsorbing CRP in the sample to the surface of the latex particles and reacting it with the anti-CRP antibody, specific aggregation corresponding to the CRP concentration occurs. Since the absorbance of the reaction changes in proportion to the amount of aggregation, the concentration of CRP in the sample is determined based on the calibration curve prepared using a standard of known CRP concentrations. The K-ASSAY® CRP (Ver.2) assay can be run using a chemistry analyzer. 6 levels of calibrators from the K-ASSAY® CRP Calibrator (Ver.2) calibrators are used for quantifying the levels of CRP present in the patient's sample.

This document describes the FDA 510(k) clearance for the K-ASSAY CRP (Ver.2) IVD device. This device is an in-vitro diagnostic test system, which means it analyzes biological samples in a lab setting rather than directly interacting with a patient.

Therefore, the concepts of "human readers," "AI assistance," "effect size," "multi reader multi case (MRMC) comparative effectiveness study," and "standalone (i.e. algorithm only without human-in-the loop performance)" are not applicable in this context. These terms are typically used for medical imaging AI/ML devices where human interpretation is involved.

For this in-vitro diagnostic device, the "acceptance criteria" and "study that proves the device meets the acceptance criteria" are related to its analytical performance characteristics when compared to a predicate device, and the reported device performance refers to the results of these analytical studies.

Here's the breakdown of the information provided within the scope of this IVD device:

1. Table of Acceptance Criteria and Reported Device Performance

For an IVD device like the K-ASSAY® CRP (Ver.2), the acceptance criteria are generally established by demonstrating equivalent or superior analytical performance compared to a legally marketed predicate device, and meeting established CLSI guidelines for accuracy, precision, linearity, and interference. The "reported device performance" refers to the actual study results for these characteristics.

• Within-Run CV: 0.8% to 2.2%
• Between-Run CV: 0.0% to 0.6%
• Within-Lot CV: 0.9% to 1.9%
• Between-Lot CV: 0.0% to 1.2%
• Total CV: 0.9% to 2.3%
  Multisite Precision (Combined Data From 3 Analyzers):
• Repeatability CV: 0.5% to 1.5%
• Between-Run CV: 0.0% to 1.1%
• Between-Day CV: 0.6% to 1.8%
• Between-Site CV: 0.9% to 1.8%
• Reproducibility CV: 1.1% to 2.5% |
  | Interference: No significant interference from common endogenous and exogenous substances (recovery within 10% of initial value). | Endogenous Substances (up to listed concentrations, no significant interference): Bilirubin C (40 mg/dL), Bilirubin F (40 mg/dL), Cholesterol (300 mg/dL), Hemoglobin (1,000 mg/dL), Intralipid (500 mg/dL), Rheumatoid Factor (1,000 IU/mL), Triglycerides (1,000 mg/dL).
  Exogenous Substances (up to listed concentrations, no significant interference): Acetaminophen (1.5 mM), Amoxicillin (400 µmol/L), Aspirin (3.6 mM), Cephalexin (360 µmol/L), Fluconazole (480 µmol/L), Ibuprofen (2.5 mg/dL), Methotrexate (1,400 µmol/L), Prednisolone (2 µmol/L), Vitamin C (500 mg/L). |
  | Method Comparison: Strong correlation and minimal bias against the predicate device. | Regression Equation: y = 1.005x - 0.002, r = 0.999 (n = 175 clinical native serum samples), where y = K-ASSAY® CRP (Ver.2), x = predicate device. |
  | Linearity: Demonstrates linearity across the claimed assay range. | Regression Equation: y = 0.9709x - 1.095, r = 0.999 (tested range: 4.6 - 441.2 mg/L). |
  | Limit of Quantitation (LoQ): Clinically acceptable LoQ (within-laboratory precision ≤ 20% CV). | Reported LoQ: 1.0 mg/L (highest observed across 3 reagent lots). Claimed LoQ: 5.0 mg/L. |
  | Matrix Comparison: No significant difference in results across different sample matrices (serum vs. plasma). | K2-EDTA Plasma vs Serum: y = 1.007x - 0.141, r = 0.999
  Li-Heparin Plasma vs Serum: y = 0.972x + 0.074, r = 0.999 |
  | Expected Values (Verification): Distribution in normal population consistent with clinical literature. | 168 normal U.S. serum samples tested; 4 out of 168 samples (>5.0 mg/L, 2.4%) consistent with literature (≤ 5 mg/L indicates apparently healthy). |

2. Sample Sizes Used for the Test Set and Data Provenance

• Method Comparison: n = 175 clinical native serum samples.
• Linearity: The number of samples/dilutions used is not explicitly stated, but the tested range was 4.6 - 441.2 mg/L.
• Limit of Quantitation (LoQ): Not specified in terms of sample size for the LoQ determination itself (typically involves low-concentration samples measured multiple times).
• Matrix Comparison: 42 donor samples (each collected into 3 different tubes: serum, K2-EDTA plasma, Li-Heparin plasma).
• Precision (Single-site): For each of the 7 samples/controls, N=240 individual measurements (2 runs/day x 2 replicates/run x 20 days x 3 lots).
• Precision (Multisite): For each of the 7 samples/controls, N=75 individual measurements (1 run/day x 5 replicates/run x 5 days x 3 analyzers).
• Interference: The number of unique samples tested for interference is not explicitly stated. Typically, a few samples (e.g., low, medium, high concentration) are spiked with interferents and compared to unspiked controls.
• Expected Values: 168 normal serum samples.
• Data Provenance: The document states for "Expected Values" that 168 normal serum samples were "taken from healthy individuals in the U.S." This indicates a U.S. origin for at least this specific study. For other studies (Method Comparison, Precision, Linearity, Interference, Matrix Comparison), the specific country of origin is not mentioned. All studies are retrospectively analyzed in the sense that they were completed performance validation studies submitted to FDA.

3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications of Those Experts

For an in-vitro diagnostic device like this CRP assay, the "ground truth" is established through highly accurate and precise reference methods or established predicate devices, adhering to rigorous analytical chemistry best practices and guidelines (e.g., CLSI standards). There isn't a panel of human "experts" like radiologists interpreting images. The "ground truth" is quantitative and objective, derived from reference measurements.

In this case:

• Method Comparison: The predicate device (K-ASSAY® CRP (3), K023828) serves as the comparator for method comparison, which represents the established "ground truth" for clinical samples.
• Linearity, LoQ, Precision, Interference, Matrix Comparison: The "ground truth" for these analytical performance studies is established by rigorous laboratory protocols, highly calibrated equipment, reference materials, and adherence to CLSI guidelines. The performance is assessed against predefined statistical criteria rather than expert consensus on individual cases.
• Expected Values: The ground truth comes from established clinical literature and verified normal ranges based on studies of healthy populations.

4. Adjudication Method for the Test Set

Not applicable for an IVD device. Adjudication methods (e.g., 2+1, 3+1) are used in studies where subjective human interpretation (e.g., image reading) requires consensus building for ground truth establishment. For quantitative IVD assays, the results are numerical and objectively measured; therefore, there's no need for adjudication.

5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done

No. As explained above, this is an in-vitro diagnostic device, not an imaging AI/ML device involving human readers.

6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) Was Done

Yes, in essence, all the analytical performance studies (Method Comparison, Linearity, LoQ, Precision, Interference, Matrix Comparison) are "standalone" in nature for an IVD. The device's performance is evaluated based solely on its ability to accurately and precisely measure CRP concentrations in samples, without any human interpretation of the measurement itself or the involvement of an "algorithm" in the AI/ML sense. The device directly processes the sample and outputs a quantitative result.

7. The Type of Ground Truth Used

The ground truth for this IVD device's performance studies is primarily based on:

• Reference Method/Predicate Device Comparison: For the method comparison study, the predicate device serves as the reference against which the new device's measurements are compared.
• Reference Materials and Calibrators: For linearity, LoQ, and precision studies, the ground truth for concentration values is established using certified reference materials and meticulously prepared calibrators with known concentrations.
• Spiked Samples: For interference studies, known amounts of interfering substances are added to samples, and the true CRP concentration (before interference) serves as the baseline ground truth.
• Clinical Literature/Established Norms: For "Expected Values," the ground truth is derived from widely accepted clinical ranges and population studies cited in the literature.

8. The Sample Size for the Training Set

This document describes a 510(k) submission for a traditional IVD device, not an AI/ML-based device. Therefore, there is no "training set" in the context of machine learning. The device's performance is based on its chemical and physical principles (latex-enhanced immunoturbidimetric assay) and validated through the analytical studies detailed.

9. How the Ground Truth for the Training Set Was Established

Not applicable, as there is no "training set" for this type of IVD device.

Ask a specific question about this device

The K-ASSAY® RF (Ver.2) assay is for the quantitative determination of human IgG rheumatoid factor antibodies in patient serum or plasma (citric acid, EDTA, or lithium heparin) based on immunoturbidimetric assay. The presence of IgG RF antibodies, in conjunction with clinical findings and other laboratory tests, is an aid in the diagnosis of rheumatord arthritis (RA). FOR IN VITRO DIAGNOSTIC USE.

The K-ASSAY® RF Calibrator (Ver.2) is intended to be used to calibrate the K-ASSAY® RF (Ver.2) immunoturbidimetric assay. FOR IN VITRO DIAGNOSTIC USE.

Not Found

The provided text is a 510(k) premarket notification letter from the FDA for a medical device called "K-ASSAY® RF (Ver.2), K-ASSAY® RF Calibrator (Ver.2)". This device is an in-vitro diagnostic test for quantitative determination of human IgG rheumatoid factor antibodies.

The letter explicitly states that the device is a "Rheumatoid Factor Immunological Test System" (Regulation Name: 21 CFR 866.5775) and is a "Class II" device.

Crucially, this document is an FDA clearance letter for a laboratory test (an in-vitro diagnostic device), not an AI/ML-based medical device that would have acceptance criteria based on performance metrics like sensitivity, specificity, or AUC, or involve human readers and their improvement with AI assistance.

Therefore, most of the requested information regarding acceptance criteria, study design for AI/ML, human readers, ground truth establishment, etc., is not applicable to this type of device and will not be found in this document.

The "acceptance criteria" for this type of device typically revolve around demonstrating substantial equivalence to a predicate device, and performance measures like precision, accuracy, linearity, measuring range, interference, and agreement studies for clinical performance. These are standard validation tests for IVD products, not AI performance metrics.

In summary, based on the provided text, I cannot provide the requested information because it pertains to an AI/ML medical device, which the K-ASSAY® RF (Ver.2) is not.

I can, however, extract the following relevant information from the document as it pertains to a medical device:

1. Device Name: K-ASSAY® RF (Ver.2), K-ASSAY® RF Calibrator (Ver.2)
2. Regulation Number: 21 CFR 866.5775
3. Regulation Name: Rheumatoid Factor Immunological Test System
4. Regulatory Class: Class II
5. Indications for Use: The K-ASSAY® RF (Ver.2) assay is for the quantitative determination of human IgG rheumatoid factor antibodies in patient serum or plasma (citric acid, EDTA, or lithium heparin) based on immunoturbidimetric assay. The presence of IgG RF antibodies, in conjunction with clinical findings and other laboratory tests, is an aid in the diagnosis of rheumatoid arthritis (RA). FOR IN VITRO DIAGNOSTIC USE. The K-ASSAY® RF Calibrator (Ver.2) is intended to be used to calibrate the K-ASSAY® RF (Ver.2) immunoturbidimetric assay. FOR IN VITRO DIAGNOSTIC USE.
6. Type of Use: Prescription Use
7. Predicate Device: The letter states the device is "substantially equivalent" to legally marketed predicate devices, but the specific predicate device is not named in this letter.

To reiterate, the questions about acceptance criteria, study design, sample sizes, experts, ground truth, MRMC studies, standalone performance, and training sets are not applicable to this medical device submission as described in the provided FDA 510(k) clearance letter.

Ask a specific question about this device

The K-ASSAY® Ferritin (2nd Gen.) assay is an in vitro diagnostic reagent for the quantitative determination of ferritin (an iron-storing protein) in human serum and plasma by immunoturbidimetric assay on the Beckman AU680 analyzer. Measurements of ferritin aid in the diagnosis of diseases affecting iron overload and iron deficiency anemia. For in vitro diagnostic use.

The K-ASSAY® Ferritin Calibrator (2nd Gen.) is an in vitro diagnostic reagent for calibration of the K-ASSAY® Ferritin (2nd Gen.) assay. For in vitro diagnostic use.

The K-ASSAY® Ferritin (2nd Gen.) assay is a latex enhanced immuno-turbidimetric assay for the quantitative in vitro determination of ferritin levels in serum and plasma (EDTA and heparin) samples.

The K-ASSAY® Ferritin (2nd Gen.) consists of two reagents. Reagent 1 contains HEPES buffer solution (50 mmol/L) and Reagent 2 contains HEPES buffer solution (50 mmol/L) and a solution of latex suspension with mouse monoclonal anti-human ferritin antibodies. Both reagents also contain less than 0:01 w/v% of sodium azide as a preservative.

The K-ASSAY® Ferritin Calibrators (2nd Gen.) are liquid stable products consisting of a human serum matrix and known quantities of human ferritin at 6 levels ranging from 0 -1,000 ng/mL (0, 25, 250, 500, 750, 1,000 ng/mL). The calibrators also contain less than 0.1 w/v% of sodium azide as a preservative.

Here's a breakdown of the acceptance criteria and the studies that prove the device meets them, based on the provided text:

Acceptance Criteria and Device Performance

Ask a specific question about this device